Every Form 4 that Vaxcyte, Inc. (PCVX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PCVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCVX filings page.
Vaxcyte, Inc. director Olivier Brandicourt reported receiving new equity awards. On January 15, 2026, he was granted 1,357 shares of Common Stock underlying restricted stock units, which will fully vest on the earlier of June 12, 2026 or the day before the next annual stockholder meeting, subject to his continuous service.
He was also granted a stock option for 6,750 shares of Common Stock, which vests monthly and will be fully vested on the same schedule, also conditioned on continued service. After the RSU grant, he directly beneficially owned 2,505 shares of Common Stock, and he held 6,750 stock options.